116 related articles for article (PubMed ID: 7378119)
1. The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
Naruszewicz M; Szostak WB; Cybulska C; Kozłowska M; Chotkowska E
Atherosclerosis; 1980 Apr; 35(4):383-92. PubMed ID: 7378119
[TBL] [Abstract][Full Text] [Related]
2. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
Brook JG; Lavy A; Aviram M; Zinder O
Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
[TBL] [Abstract][Full Text] [Related]
3. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
Weisweiler P; Schwandt P
Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
Rössner S; Orö L
Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
[TBL] [Abstract][Full Text] [Related]
5. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Vessby B; Lithell H; Gustafsson IB; Borberg J
Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
[TBL] [Abstract][Full Text] [Related]
6. The effect of short-term and prolonged fructose intake on VLDL-TG and relative properties on apo CIII1 and apo CII in the VLDL fraction in type IV hyperlipoproteinaemia.
Cybulska B; Naruszewicz M
Nahrung; 1982; 26(3):253-61. PubMed ID: 7110307
[TBL] [Abstract][Full Text] [Related]
7. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
9. Effect of clofibrate on the composition of very low and low density lipoprotein subfractions in type III hyperlipoproteinaemia.
Ballantyne D; Ballantyne FC; Stromberg P; Third JL; Bedford DK
Clin Chim Acta; 1978 Feb; 83(1-2):117-22. PubMed ID: 202421
[TBL] [Abstract][Full Text] [Related]
10. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
11. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
12. Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.
Kamanna VS; Newman HA; Patel ST; Tehim AK; Witiak DT; Feller DR
Lipids; 1989 Jan; 24(1):25-32. PubMed ID: 2747427
[TBL] [Abstract][Full Text] [Related]
13. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
Gustafson A
Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
[No Abstract] [Full Text] [Related]
14. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye ER; Sutherland WH; Temple Wa
N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
Larsen ML; Illingworth DR; O'Malley JP
Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
[TBL] [Abstract][Full Text] [Related]
17. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
Schwandt P; Weisweiler P; Drosner M; Janetschek P
Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
[No Abstract] [Full Text] [Related]
18. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
19. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
Simons LA; Hickie JB; Balasubramaniam S
Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
[TBL] [Abstract][Full Text] [Related]
20. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
